Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05VXQ
|
|||
| Former ID |
DIB002362
|
|||
| Drug Name |
SRSC-355
|
|||
| Synonyms |
SGX-211; SGX-355; Neuropathic pain therapeutic (systemic depot, CK polymer), Sirus
Click to Show/Hide
|
|||
| Indication | Neuropathic pain [ICD-11: 8E43.0] | Terminated | [1] | |
| Company |
Sirus Pharmaceuticals Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium channel unspecific (NaC) | Target Info | Modulator | [2] |
| KEGG Pathway | Dopaminergic synapse | |||
| Reactome | Interaction between L1 and Ankyrins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018179) | |||
| REF 2 | WO patent application no. 2013,0439,25, Sodium channel blockers reduce glucagon secretion. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.